8.8785
price up icon1.94%   0.2085
 
loading
Precedente Chiudi:
$8.67
Aprire:
$8.57
Volume 24 ore:
288.60K
Relative Volume:
0.11
Capitalizzazione di mercato:
$1.06B
Reddito:
$631.73M
Utile/perdita netta:
$-239.78M
Rapporto P/E:
-4.3953
EPS:
-2.02
Flusso di cassa netto:
$-33.45M
1 W Prestazione:
-7.75%
1M Prestazione:
-17.33%
6M Prestazione:
-56.10%
1 anno Prestazione:
-75.53%
Intervallo 1D:
Value
$8.53
$8.915
Intervallo di 1 settimana:
Value
$8.53
$9.65
Portata 52W:
Value
$8.53
$37.73

10 X Genomics Inc Stock (TXG) Company Profile

Name
Nome
10 X Genomics Inc
Name
Telefono
(925) 401-7300
Name
Indirizzo
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Name
Dipendente
1,306
Name
Cinguettio
@10xgenomics
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
TXG's Discussions on Twitter

Confronta TXG con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Health Information Services icon
TXG
10 X Genomics Inc
8.865 1.06B 631.73M -239.78M -33.45M -2.02
Health Information Services icon
VEEV
Veeva Systems Inc
225.29 37.08B 2.75B 714.14M 1.09B 4.33
Health Information Services icon
DOCS
Doximity Inc
57.73 10.64B 516.85M 174.11M 217.38M 0.87
Health Information Services icon
TEM
Tempus Ai Inc
47.51 8.13B 640.44M -743.28M -206.93M -11.29
Health Information Services icon
HQY
Healthequity Inc
87.17 7.54B 1.15B 96.70M -161.99M 1.09
Health Information Services icon
WAY
Waystar Holding Corp
36.92 6.36B 906.14M -52.62M 89.62M -0.3621

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-13 Downgrade Leerink Partners Outperform → Market Perform
2024-09-03 Iniziato Leerink Partners Outperform
2024-07-22 Aggiornamento Jefferies Hold → Buy
2024-07-18 Downgrade JP Morgan Overweight → Neutral
2024-07-10 Downgrade Deutsche Bank Buy → Hold
2024-06-27 Downgrade Wolfe Research Outperform → Peer Perform
2024-06-25 Downgrade Guggenheim Buy → Neutral
2024-06-03 Ripresa Jefferies Hold
2024-05-01 Downgrade TD Cowen Buy → Hold
2023-12-14 Iniziato Guggenheim Buy
2023-12-13 Iniziato Wolfe Research Outperform
2023-12-12 Aggiornamento BofA Securities Underperform → Neutral
2023-07-05 Ripresa JP Morgan Overweight
2023-05-10 Iniziato Barclays Overweight
2023-03-31 Iniziato Stephens Overweight
2023-02-02 Iniziato UBS Neutral
2022-12-14 Iniziato Deutsche Bank Buy
2022-08-18 Downgrade Goldman Neutral → Sell
2022-07-25 Iniziato Canaccord Genuity Buy
2022-07-15 Downgrade BofA Securities Neutral → Underperform
2022-07-15 Downgrade William Blair Outperform → Mkt Perform
2021-10-15 Ripresa Cowen Outperform
2021-09-14 Downgrade BofA Securities Buy → Neutral
2021-03-15 Iniziato William Blair Outperform
2020-12-02 Iniziato Goldman Neutral
2020-09-09 Iniziato Morgan Stanley Overweight
2020-07-10 Iniziato Stifel Buy
2020-03-05 Iniziato Guggenheim Buy
2020-01-07 Iniziato Citigroup Buy
2019-10-07 Iniziato BofA/Merrill Buy
2019-10-07 Iniziato Cowen Outperform
2019-10-07 Iniziato JP Morgan Overweight
2019-09-24 Iniziato Evercore ISI Outperform
Mostra tutto

10 X Genomics Inc Borsa (TXG) Ultime notizie

pulisher
Apr 01, 2025

IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Apr 01, 2025
pulisher
Mar 28, 2025

10X Genomics stock plunges to 52-week low of $9.27 By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

10X Genomics stock plunges to 52-week low of $9.27 - Investing.com

Mar 28, 2025
pulisher
Mar 27, 2025

We Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business Growth - Yahoo Finance

Mar 27, 2025
pulisher
Mar 21, 2025

10x Genomics Comments on Second UPC Preliminary Injunction Decis - GuruFocus.com

Mar 21, 2025
pulisher
Mar 20, 2025

10x Genomics: Lower Cost Innovation May Drive A Rebound - Seeking Alpha

Mar 20, 2025
pulisher
Mar 18, 2025

These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company

Mar 18, 2025
pulisher
Mar 11, 2025

Long Read Sequencing Market Top Companies Study10X Genomics, - openPR

Mar 11, 2025
pulisher
Mar 10, 2025

Bruker motion backfires in US patent dispute with 10x Genomics, Harvard - MLex

Mar 10, 2025
pulisher
Mar 09, 2025

10x Genomics IncOrdinary SharesClass A to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 08, 2025

10x Genomics’ (TXG) Sell (E+) Rating Reiterated at Weiss Ratings - Defense World

Mar 08, 2025
pulisher
Mar 06, 2025

Citigroup Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock Price - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Strategic Move: Healthcare Giant Zimmer Biomet Taps Communications Veteran from 10x Genomics - Stock Titan

Mar 06, 2025
pulisher
Mar 05, 2025

10x Genomics gets injunction against Parse Biosciences' ATAC Products - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

10x Genomics Dodges Appeal In DNA Analysis Patent Clash - Law 360 UK

Mar 05, 2025
pulisher
Mar 05, 2025

10x genomics CEO Serge Saxonov sells $84,393 in stock By Investing.com - Investing.com Australia

Mar 05, 2025
pulisher
Mar 05, 2025

Rhumbline Advisers Sells 1,641 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

10x genomics CEO Serge Saxonov sells $84,393 in stock - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Sanctuary Advisors LLC Purchases 6,474 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Short Interest in 10x Genomics, Inc. (NASDAQ:TXG) Expands By 34.4% - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

10x Genomics Secures Injunction Against Parse Biosciences' Plann - GuruFocus.com

Mar 03, 2025
pulisher
Mar 03, 2025

10x Genomics Secures Injunction Against Parse Biosciences’ Planned ATAC Products - The Malaysian Reserve

Mar 03, 2025
pulisher
Mar 03, 2025

10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

10x Genomics secures injunction against Parse Biosciences - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

10x Genomics gets injunction against Parse Biosciences' ATAC Products (TXG:NASDAQ) - Seeking Alpha

Mar 03, 2025
pulisher
Mar 03, 2025

10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products – Company Announcement - Financial Times

Mar 03, 2025
pulisher
Mar 02, 2025

10 Promising Biotech Stocks to Invest in (March 2025) - Securities.io

Mar 02, 2025
pulisher
Mar 01, 2025

ARK Investment Management LLC Purchases 1,193,712 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

SVB Wealth LLC Acquires Shares of 522,609 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Ieq Capital LLC Purchases 50,722 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

ING Groep NV Acquires New Shares in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

10x Genomics, Inc. (NASDAQ:TXG) CEO Sells $56,368.44 in Stock - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Director of 10x Genomics Picks Up 184% More Stock - Simply Wall St

Feb 27, 2025
pulisher
Feb 27, 2025

Oxford Nanopore Expands Compatibility With 10x Genomics To Unlock Deeper Insights in Single-Cell Transcriptomics - Technology Networks

Feb 27, 2025
pulisher
Feb 26, 2025

Insider Buying: 10x Genomics, Inc. (NASDAQ:TXG) Director Buys 40,000 Shares of Stock - MarketBeat

Feb 26, 2025
pulisher
Feb 26, 2025

10x genomics’ president sells $50,602 in stock - Investing.com India

Feb 26, 2025
pulisher
Feb 26, 2025

10x genomics CEO Serge Saxonov sells $56,346 in stock - Investing.com India

Feb 26, 2025
pulisher
Feb 26, 2025

10x genomics CEO Serge Saxonov sells $56,346 in stock By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

10x genomics' president sells $50,602 in stock - Investing.com

Feb 26, 2025
pulisher
Feb 25, 2025

10x genomics director Alan Mateo acquires $445,572 in stock - Investing.com

Feb 25, 2025
pulisher
Feb 25, 2025

10x Genomics Director Mateo Alan Acquires 40,000 Shares - TradingView

Feb 25, 2025
pulisher
Feb 24, 2025

10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis - BioSpace

Feb 24, 2025
pulisher
Feb 23, 2025

10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, - GuruFocus.com

Feb 23, 2025
pulisher
Feb 23, 2025

10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis – Company AnnouncementFT.com - Financial Times

Feb 23, 2025
pulisher
Feb 23, 2025

Can 10x Genomics' New 8-Million Cell Platform Transform Genomic Research? - Stock Titan

Feb 23, 2025
pulisher
Feb 22, 2025

Harvard, 10x Genomics Settle Patent Dispute With Vizgen - The Harvard Crimson

Feb 22, 2025
pulisher
Feb 21, 2025

10x Genomics, Inc. (NASDAQ:TXG) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St

Feb 21, 2025
pulisher
Feb 21, 2025

Alberta Investment Management Corp Makes New $3.21 Million Investment in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Feb 21, 2025
pulisher
Feb 20, 2025

Weiss Ratings Reiterates Sell (E+) Rating for 10x Genomics (NASDAQ:TXG) - Defense World

Feb 20, 2025
pulisher
Feb 19, 2025

10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference - The Eastern Progress Online

Feb 19, 2025
pulisher
Feb 19, 2025

10x Genomics, Inc. (NASDAQ:TXG) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Feb 19, 2025

10 X Genomics Inc Azioni (TXG) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

10 X Genomics Inc Azioni (TXG) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Saxonov Serge
Chief Executive Officer
Feb 28 '25
Sale
10.63
7,942
84,393
871,540
$34.67
price down icon 1.79%
$4.565
price up icon 2.48%
$19.50
price down icon 0.07%
$22.36
price down icon 2.40%
$17.70
price down icon 0.56%
health_information_services WAY
$36.45
price down icon 1.41%
Capitalizzazione:     |  Volume (24 ore):